National Blood Clot Alliance

National City, United States

National Blood Clot Alliance

National City, United States
SEARCH FILTERS
Time filter
Source Type

Streiff M.B.,Sidney Kimmel Comprehensive Cancer Center | Holmstrom B.,H. Lee Moffitt Cancer Center and Research Institute | Ashrani A.,Mayo Clinic Cancer Center | Bockenstedt P.L.,University of Michigan | And 25 more authors.
JNCCN Journal of the National Comprehensive Cancer Network | Year: 2015

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer. © JNCCN-Journal of the National Comprehensive Cancer Network.


Aggarwal A.,George Washington University | Fullam L.,National Blood Clot Alliance | Brownstein A.P.,National Blood Clot Alliance | Maynard G.A.,National Blood Clot Alliance | And 9 more authors.
Cancer Investigation | Year: 2015

Patients with cancer are at increased risk for venous thromboembolism (VTE). An online survey to measure PE/DVT terminology awareness and understanding of VTE risks revealed 24% and 15% of the 500 cancer patients surveyed had heard of term DVT/PE; 19% and 17% could name signs/symptoms of DVT/PE; 3% recognized cancer treatments as risk factors for DVT/PE. Only 25% of the patients received prevention education from providers; <50% received VTE prophylaxis. Cancer patient awareness of VTE terminology and cancer and/or its treatment as risk for VTE is low. More effective patient/physician dialogue about VTE risk and thromboprophylaxis is needed. © 2015 Informa Healthcare USA, Inc.


Trademark
National Blood Clot Alliance and National Alliance For Thrombosis & Thrombophilia | Date: 2011-02-15

Pamphlets, newsletters, brochures and leaflets on the subject of blood clots and clotting disorders. Educational services, namely, providing seminars, conferences, symposia, classes, forums, workshops and online interactive classes on the subject of blood clots and clotting disorders. Providing healthcare information about blood clots and clotting disorders.


Trademark
National Blood Clot Alliance and National Alliance For Thrombosis & Thrombophilia | Date: 2012-05-15

Pamphlets, newsletters, brochures and leaflets on the subject of blood clots and clotting disorders.


Trademark
National Blood Clot Alliance | Date: 2015-03-20

Pamphlets, newsletters, brochures and leaflets on the subject of blood clots and clotting disorders.


Trademark
National Blood Clot Alliance and National Alliance For Thrombosis & Thrombophilia | Date: 2010-03-23

pamphlets, newsletters, brochures and leaflets on the subject of blood clots and clotting disorders.

Loading National Blood Clot Alliance collaborators
Loading National Blood Clot Alliance collaborators